North America Hematology Analyzers And Reagents Market

The North America hematology analyzers and reagents market was valued USD 2,670.0 million in 2020 and is estimated to reach USD YY million by 2029, at a CAGR of 7.1% during the forecast period (2022-2029).

The North American segment is estimated to account for a share of approximately 33.89% of the hematology analyzers and reagents market by 2020 and is anticipated to grow to YY by 2029.

North America has the largest market share due to the rising incidence of patients suffering from blood disorders, the growing prevalence of target diseases, and the rising demand for blood transfusions in the region. For instance, anemia, a common disorder, affects more than three million Americans, particularly women of childbearing age.

As per the World Federation of Hemophilia 2018 report, in 2018, there were about 17,757 people diagnosed with hemophilia in the United States. 

Furthermore, in 2019, the number of people with hemophilia in the United States increased to about 20,000 individuals, as per NHF (National Health Federation).

In addition, According to the Leukemia and Lymphoma Society, every three minutes, a person in the United States is diagnosed with blood cancer. About 176,200 people in the United States were diagnosed with leukemia, lymphoma, or myeloma in 2019.

Many market players are present in the country and are continuously focusing on developing and introducing novel products. For instance, In December 2019, Beckman Coulter subsidiary of Danaher Corporation launched a new DxH 690T hematology analyzer designed to help laboratories streamline workflow and maximize uptime. 

Furthermore, in April 2019, Ortho Clinical Diagnostics, in collaboration with Diazyme Laboratories Inc., launched its D-Dimer assay, the most modern offering in Ortho’s MicroTip Partnership Assay (MPA) program for coagulation testing in the US.

Moreover, In the United States, several associations are serving both clinicians and scientists across the world who are working to overcome such blood diseases.

In addition, many cities in the state are international leaders in diagnosing and treating blood diseases and collaborate in many research projects to improve diagnosis and treatment options for blood diseases. 

Additionally, the growing awareness regarding chronic diseases and the importance of sustaining good health among the patient population is expected to boost the global hematology analyzers and reagent market growth.

Combined with this, the increase in the prevalence of diseases like blood cell cancer, sickle cell anemia, and HIV, amongst others, is expected to drive the global hematology analyzers and reagents market positively.

Further, in November 2020, Sysmex America announced that it would distribute the FDA-cleared ClearVision DC-1 for low-volume hematology laboratories in the United States and Canada. Thus, owing to the abovementioned factors, the market is expected to witness significant growth in the forecast period in the North American region. 

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com